Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18553281 | 0.94 | AHR (0.53) | AHRKIF11ALDH1A1GPR3HSD17B10 | |
| SCHEMBL18666428 | 0.88 | CDK4 (0.43) | AHRALDH1A1HSD17B10CYP1A2ALOX5 | |
| SCHEMBL18666121 | 0.83 | CYP1A2 (0.40) | AHRALDH1A1HSD17B10CYP1A2ALOX5 | |
| SCHEMBL21128608 | 0.82 | AHR (0.49) | AHRKIF11ALDH1A1GPR3HSD17B10 | |
| SCHEMBL18666044 | 0.81 | AHR (0.50) | AHRKIF11ALDH1A1GPR3HSD17B10 | |
| SCHEMBL21781179 | 0.80 | CYP1A2 (0.47) | AHRKIF11ALDH1A1GPR3HSD17B10 | |
| SCHEMBL19831835 | 0.79 | AHR (0.53) | AHRKIF11ALDH1A1GPR3HSD17B10 | |
| SCHEMBL18553445 | 0.79 | CYP1A2 (0.40) | AHRALDH1A1HSD17B10CYP1A2TOP2A | |
| SCHEMBL18553436 | 0.79 | AHR (0.49) | AHRKIF11ALDH1A1GPR3HSD17B10 | |
| SCHEMBL787216 | 0.78 | ALOX5 (0.59) | AHRKIF11ALDH1A1GPR3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934308-B2 | Compound for organic electronic element, organic electronic element using same, and electronic device comprising same | DUK SAN NEOLUX CO., LTD. (KR) | 2021-03-02 | — | — | US | disclosed |
| WO-2017048025-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING SAME, AND ELECTRONIC DEVICE COMPRISING SAME | 덕산네오룩스 주식회사 | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934308-B2 | Compound for organic electronic element, organic electronic element using same, and electronic device comprising same | OR51E2, NFE2L2, ETV6 | AHR 2334/4885KIF11 2204/4885ALDH1A1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.